BMO Capital Reiterates Outperform Rating on Dyne Therapeutics (DYN)

BMO Capital analyst Kostas Biliouris reiterated an Outperform rating and $50.00 price target on Dyne Therapeutics (NASDAQ: DYN)

The analyst comments "DYN is under significant pressure YTD (-52% vs XBI: -3%), mainly due to lack of clarity around DYNE-101 (DM1) regulatory pathway. In 2025, we await FDA's decision on DYNE-101 pathway, wherein a traditional-approval pathway (prob=60%) would disappoint investors (due to management's confidence in accelerated-approval and competitive dynamics vs. Avidity), driving ~20-30% downside and creating an attractive entry point. Conversely, an accelerated-approval pathway (prob=40%) would strengthen DYNE competitiveness in DM1, driving ~10-50% upside. Either way, we see DYN as undervalued, especially given '251 potential ~YE26 approval (DMD, peak sales≈$550M)."

For an analyst ratings summary and ratings history on Dyne Therapeutics click here. For more ratings news on Dyne Therapeutics click here.

Shares of Dyne Therapeutics closed at $11.40 yesterday.

You May Also Be Interested In

• Stifel Starts Arrowhead Pharma (ARWR) at Buy
• Sanuwave Q2 2026 revenue tops revised guidance range
• Penguin Solutions plans $650M convertible notes offering due 2031